GlassScriptPhysician profile
Angela Escobar
NPI 1760012835
$7,325.97
in general payments reported to CMS, 2019-2025
49 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,601 · 2022: $1,708 · 2023: $1,255 · 2024: $1,171 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.11 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,172.29 | 2021-2025 | Airsupra, Tezspire, Farxiga |
| Glaxosmithkline, LLC. | $447.31 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $442.97 | 2021-2022 | |
| Novo Nordisk INC | $418.31 | 2021-2023 | Saxenda, Wegovy, Ozempic |
| Amgen INC. | $407.48 | 2021-2025 | Tezspire, Otezla, Repatha |
| Genzyme Corporation | $357.14 | 2023-2025 | |
| Lilly USA, LLC | $345.98 | 2021-2025 | Jardiance, Emgality, Ebglyss |
| Takeda Pharmaceuticals U.S.A., INC. | $298.81 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $282.66 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $268.85 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $231.27 | 2021-2023 | Camzyos, Eliquis |
| Abbvie INC. | $202.56 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $191.84 | 2021-2025 | |
| Csl Behring | $179.05 | 2024-2025 | Haegarda, Andembry, Hizentra |
| Bayer Healthcare Pharmaceuticals INC. | $168.53 | 2021-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.